Phathom Pharmaceuticals (PHAT) News Today $11.91 +0.96 (+8.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.92 +0.02 (+0.13%) As of 08/22/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingAugust 20 at 8:00 AM | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.4% - Still a Buy?August 16, 2025 | marketbeat.comPhathom Pharmaceuticals (PHAT) Gets a Buy from GuggenheimAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Gets a Buy from H.C. WainwrightAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comPhathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineAugust 9, 2025 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | insidermonkey.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 11.7% Higher - Here's What HappenedAugust 8, 2025 | marketbeat.comPhathom (PHAT) Q2 Revenue Jumps 441%August 8, 2025 | theglobeandmail.comPhathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growthAugust 8, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comPhathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Buy" by BrokeragesAugust 7, 2025 | marketbeat.comXTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)August 7, 2025 | marketbeat.comCraig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)August 6, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayAugust 1, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7% - Here's WhyJuly 29, 2025 | marketbeat.comPhathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025July 28, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.2% Higher - Here's WhyJuly 26, 2025 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 1,692 Shares of StockJuly 19, 2025 | marketbeat.comRobert Charles Breedlove Sells 1,692 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 19, 2025 | insidertrades.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6% - Should You Sell?July 15, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from BrokeragesJuly 13, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.4% - Here's What HappenedJuly 7, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's WhyJuly 1, 2025 | marketbeat.comPhathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New MechanismJune 25, 2025 | seekingalpha.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - MorningstarJune 24, 2025 | morningstar.comMPhathom Pharmaceuticals, Inc. (PHAT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 23, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?June 23, 2025 | marketbeat.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate SecretaryJune 23, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesJune 18, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?June 16, 2025 | marketbeat.comPhathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032June 16, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?June 12, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?June 11, 2025 | marketbeat.comTiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: BuyJune 10, 2025 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What HappenedJune 9, 2025 | marketbeat.comPhathom: Share Price Surge On Patent News May Not Stop The Rot For LongJune 9, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)June 9, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig HallumJune 9, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC WainwrightJune 9, 2025 | marketbeat.comPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032June 8, 2025 | finanznachrichten.deStifel analysts affirm Buy rating for Phathom Pharmaceuticals stockJune 7, 2025 | investing.comWellington Management Group LLP Sells 37,388 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)June 7, 2025 | marketbeat.comPhathom Pharmaceuticals shares soar on FDA exclusivity grantJune 6, 2025 | uk.finance.yahoo.comPhathom Pharmaceuticals price target raised to $29 from $23 at Cantor FitzgeraldJune 6, 2025 | msn.comPhathom surges 125% after FDA grants petition on Voquezna exclusivityJune 6, 2025 | msn.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCJune 6, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Sees Unusually-High Trading Volume - Here's WhyJune 6, 2025 | marketbeat.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.380.66▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼24▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Crinetics Pharmaceuticals News HUTCHMED News Ultragenyx Pharmaceutical News MorphoSys News Arrowhead Pharmaceuticals News NewAmsterdam Pharma News Immunovant News Recursion Pharmaceuticals News Catalyst Pharmaceuticals News Kiniksa Pharmaceuticals International News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access